



-1-

WD

(Box Seg)

GA (1) 1642
~~11/12/99~~

Attorney's Docket No. L0461/7047

RECEIVED

DEC 02 1999

TECH CENTER 1600/2900

#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Martelange et al.
Serial No.: 09/183,789
Filed: October 30, 1998
For: TUMOR ASSOCIATED NUCLEIC ACIDS AND USES THEREFOR
Examiner: A. Harris
Art Unit: 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on November 24, 1999.

RECEIVED

1-7-99
DF
20



Monica E. Zombori

TECH C. 1600/2900
REC'D 11/24/99

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- Copy of Notice to Comply with Requirements for Sequence Disclosures
- Statement Pursuant to 37 C.F.R. 1.821(f) and 1.825(a) and (b)
- Sequence Listing with Identical Computer Readable Diskette
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

If the enclosed check is considered insufficient, then please charge the balance to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,



John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel. (617) 720-3500

ATTORNEY DOCKET NO. L0461/7047
Date: November 24, 1999
X12/12/99

419988.1

12/17/1999 DWILLIA1 000
110.
01 FC:115



Application No.: 09/183,789

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: _____

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



-1-


Attorney's Docket No. L0461/7047

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Martelange et al.
Serial No.: 09/183,789
Filed: October 30, 1998
For: TUMOR ASSOCIATED NUCLEIC ACIDS AND USES THEREFOR
Examiner: A. Harris
Art Unit: 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on November 24, 1999November 24, 1999


Monica E. Zombori

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:

STATEMENT PURSUANT TO 37 CFR 1.821(f) AND 37 CFR 1.825 (a) and (b)

This is responsive to the communication from the Examiner mailed on November 12, 1999 (notice to comply with sequence listing requirements). This statement is made pursuant to 37 CFR 1.821 (f), and 37 CFR 1.825 (a) and (b). Applicants submit herewith a substitute copy of the written sequence listing and a computer readable diskette to comply with the sequence requirements. The amendments to the sequence listing relate only to eliminating the errors detected in the previously submitted sequence listing. No new matter has been added.

Applicants' attorney states that the information recorded in computer readable form is identical to the written sequence listing and that neither the computer readable form nor the written sequence listing contain new matter.

Respectfully submitted,


John R. Van Amsterdam
Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel. (617) 720-3500

ATTORNEY DOCKET NO. L0461/7047
Date: November 24, 1999
X12/12/99